Telomir Pharmaceuticals, Inc. Common Stock
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson's disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer's dis… Read more
Telomir Pharmaceuticals, Inc. Common Stock (TELO) - Net Assets
Latest net assets as of September 2025: $6.98 Million USD
Based on the latest financial reports, Telomir Pharmaceuticals, Inc. Common Stock (TELO) has net assets worth $6.98 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.40 Million) and total liabilities ($422.81K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.98 Million |
| % of Total Assets | 94.29% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Telomir Pharmaceuticals, Inc. Common Stock - Net Assets Trend (2021–2024)
This chart illustrates how Telomir Pharmaceuticals, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Telomir Pharmaceuticals, Inc. Common Stock (2021–2024)
The table below shows the annual net assets of Telomir Pharmaceuticals, Inc. Common Stock from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | $643.04K | -81.30% |
| 2023-09-30 | $3.44 Million | +466.83% |
| 2022-09-30 | $-937.28K | -1027.47% |
| 2021-09-30 | $-83.13K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Telomir Pharmaceuticals, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3045872700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $31.24 Million | 4858.18% |
| Total Equity | $643.04K | 100.00% |
Telomir Pharmaceuticals, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Telomir Pharmaceuticals, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
New Delhi Television Limited
NSE:NDTV
|
$25.69 Million |
|
Hiroca Holdings Ltd
TW:1338
|
$25.70 Million |
|
LabGenomics Co. Ltd
KQ:084650
|
$25.72 Million |
|
Beijing JIAYU Door Window Curtain
SHE:300117
|
$25.72 Million |
|
TJ media Co. Ltd
KQ:032540
|
$25.68 Million |
|
Big Sunshine Co Ltd
TW:1475
|
$25.67 Million |
|
DIVA Laboratories Ltd
TWO:4153
|
$25.67 Million |
|
PT Wijaya Karya (Persero) Tbk
F:5AA
|
$25.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Telomir Pharmaceuticals, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,438,204 to 643,037, a change of -2,795,167 (-81.3%).
- Net loss of 16,532,716 reduced equity.
- New share issuances of 6,832,973 increased equity.
- Other factors increased equity by 6,904,576.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.53 Million | -2571.04% |
| Share Issuances | $6.83 Million | +1062.61% |
| Other Changes | $6.90 Million | +1073.74% |
| Total Change | $- | -81.30% |
Book Value vs Market Value Analysis
This analysis compares Telomir Pharmaceuticals, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 62.02x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-09-30 | $0.00 | $1.35 | x |
| 2022-09-30 | $-0.03 | $1.35 | x |
| 2023-09-30 | $0.12 | $1.35 | x |
| 2024-09-30 | $0.02 | $1.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Telomir Pharmaceuticals, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2571.04%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.06x
- Recent ROE (-2571.04%) is below the historical average (-737.81%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-129.82K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-760.42K |
| 2023 | -380.19% | 0.00% | 0.00x | 1.39x | $-13.42 Million |
| 2024 | -2571.04% | 0.00% | 0.00x | 2.06x | $-16.60 Million |
Industry Comparison
This section compares Telomir Pharmaceuticals, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | $6.98 Million | 0.00% | 0.06x | $25.69 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |